Related Experiment Video
Updated: Aug 24, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses
Saiko Sugiura1, Fumi Goshima, Hiroki Takakuwa
1Department of Otorhinolaryngology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Objective:
Attenuated, replication-competent herpes simplex viruses (HSVs) have shown promise as antitumor agents for cancer therapy. In this study, we sought to develop a novel type of oncolytic HSV with more potent antitumor activity for use in localized malignant tumors.
Study Design:
A new, attenuated multimutated HSV (termed HL) was developed, and then a highly metastatic murine fibrosarcoma cell line, NfSa Y83, was injected into the necks or flanks of immunocompetent C3H mice. The mice were treated with attenuated HSV mutants by intratumoral injection, and antitumor efficacy was assessed by measuring tumor dimensions and overall survival rates.
Results:
Treatment with intratumoral injection of HL resulted in marked regression of tumors. In fact, roughly 75% of flank tumors and 50% of neck tumors were completely eradicated.
Conclusion:
A novel type of attenuated HSV recombinant HL demonstrated a remarkable antitumor efficacy in a localized tumor model in mice.
Insights
A novel herpes simplex virus (HSV) therapy demonstrated significant success in treating localized tumors. This oncolytic virus therapy led to substantial tumor regression and eradication in a mouse model.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Attenuated, replication-competent herpes simplex viruses (HSVs) show potential as oncolytic agents for cancer treatment.
- There is a need for novel oncolytic HSV with enhanced antitumor activity for localized malignant tumors.
Purpose of the Study:
- To develop and evaluate a novel, attenuated, multimutated oncolytic herpes simplex virus (HSV) recombinant, termed HL.
- To assess the antitumor efficacy of the novel HSV recombinant HL in a murine model of localized malignant tumors.
Main Methods:
- A new attenuated multimutated HSV (HL) was engineered.
- A highly metastatic murine fibrosarcoma cell line (NfSa Y83) was implanted in immunocompetent C3H mice.
- Mice received intratumoral injections of the HL virus, and antitumor effects were measured by tumor dimensions and survival rates.
Main Results:
- Intratumoral injection of the HL virus resulted in significant tumor regression.
- Approximately 75% of flank tumors and 50% of neck tumors were completely eradicated in the treated mice.
- The HL virus demonstrated marked antitumor efficacy in the localized tumor model.
Conclusions:
- The novel attenuated HSV recombinant HL exhibits remarkable antitumor efficacy.
- This oncolytic HSV therapy holds promise for treating localized malignant tumors.
- Further research into this oncolytic HSV approach is warranted for cancer therapy.
